5-(5-p-tolylamino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-(5-p-tolylamino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester
• 英文别名: ethyl 5-[[5-(4-methylanilino)-1H-1,2,4-triazol-3-yl]sulfanylmethyl]furan-2-carboxylate
• 化学式: C₁₇H₁₈N₄O₃S
• 分子量: 358.421
• InChiKey: IUVXVZQXZGZLMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• 1,2,4-triazole derivatives, compositions, process of making and methods of use
  申请人：Marino P. Joseph

  公开号：US20050267185A1

  公开（公告）日：2005-12-01

  Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

  本发明的化合物是非肽类、可逆抑制剂，用于治疗通过血管生成介导的疾病，如癌症、血管瘤、增生性视网膜病变、类风湿性关节炎、动脉粥样硬化新生血管形成、牛皮癣、眼部新生血管形成和肥胖症。
• COMPOUNDS AND METHODS
  申请人：SmithKline Beecham Corporation

  公开号：EP1223932A1

  公开（公告）日：2002-07-24
• EP1223932A4
  申请人：——

  公开号：EP1223932A4

  公开（公告）日：2003-01-15
• US7304082B2
  申请人：——

  公开号：US7304082B2

  公开（公告）日：2007-12-04
• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSES ET METHODES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2001024796A1

  公开（公告）日：2001-04-12

  Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.